Response to "Letter to the Editor: Vaccine Failures in Pediatric Cases Caused by Streptococcus pneumoniae Serotype 19A"

Gonullu E., Soysal A., Yildiz İ., Aydemir G., Tunc T., Karabocuoglu M.

HUMAN VACCINES & IMMUNOTHERAPEUTICS, cilt.16, sa.10, ss.2511-2512, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Kısa Makale
  • Cilt numarası: 16 Sayı: 10
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/21645515.2020.1769397
  • Dergi Adı: HUMAN VACCINES & IMMUNOTHERAPEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2511-2512
  • İstanbul Üniversitesi Adresli: Hayır

Özet

We are happy to answer to the Letter from Ozkaya-Parlakay et al. to the Editor commenting on our recent paper, 1 (A) over cap investigated (A) over cap impact of the 13- valent pneumococcal conjugate vaccine (PCV13) (A) over cap (A) over cap on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children (a) over cap parts per thousand alpha 5 years after its implementation into the national immunization program (NIP) of Turkey. (A) over cap (A) over cap Ozkaya-Parlakay et al. draw attention to vaccine failure and importance of continuous (A) over cap surveillance of relevant disease especially in the perspective of (A) over cap Streptococcus pneumoniae (A) over cap serotype 19A. They supported their opinion by their clinical observation of seven children who were vaccinated with PCV13 developed empyema and meningitidis caused by (A) over cap Streptococcus pneumoniae (A) over cap serotype 19A & 8232; in Turkey.